Advertisement
Advertisement
ABCL
AbCellera Biologics Inc. Common Shares
5.92
USDSponsored
-0.17
-2.79%
Aug 05, 15:58 UTC -4
Closed
After-Market
5.71
-0.21
-3.55%
ABCL Earnings Reports
Positive Surprise Ratio
ABCL beat 10 of 22 last estimates.
45%
Next Report
Today AMC
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$7.94M
/-$0.14
Implied change from Q1 26 (Revenue/ EPS)
-4.51%
/--
Implied change from Q2 25 (Revenue/ EPS)
-53.53%
/+16.67%
AbCellera Biologics Inc. Common Shares earnings per share and revenue
On May 11, 2026, ABCL reported earnings of -0.14 USD per share (EPS) for Q1 26, beating the estimate of -0.19 USD, resulting in a 29.86% surprise. Revenue reached 8.31 million, compared to an expected 5.97 million, with a 39.20% difference. The market reacted with a +0.19% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of -0.14 USD, with revenue projected to reach 7.94 million USD, implying an increase of 0.00% EPS, and decrease of -4.51% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Recursion Pharmaceuticals, Inc. Class A Common Stock
Report Date
Aug 05, 2026 For Q2 26
Estimate
-$0.23
Actual
-$0.25
Surprise
-4.73%
EyePoint, Inc. Common Stock
Report Date
Aug 05, 2026 For Q2 26
Estimate
-$0.97
Actual
-$1.09
Surprise
-12.31%
Mannkind Corporation
Report Date
Aug 05, 2026 For Q2 26
Estimate
$0.00
Actual
-$0.06
Surprise
-2,207.69%
Emergent Biosolutions, Inc.
Report Date
Aug 05, 2026 For Q2 26
Estimate
$0.11
Actual
$0.60
Surprise
+440.05%
Vanda Pharmaceuticals Inc.
Report Date
Aug 05, 2026 For Q2 26
Estimate
-$0.59
Actual
-$1.04
Surprise
-73.54%
Alpha Teknova, Inc. Common Stock
Report Date
Aug 05, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.06
Surprise
+31.58%
Royalty Pharma plc Class A Ordinary Shares
Report Date
Aug 05, 2026 For Q2 26
Estimate
$1.30
Actual
$1.32
Surprise
+1.30%
Revolution Medicines, Inc. Common Stock
Report Date
Aug 05, 2026 For Q2 26
Estimate
-$2.01
Actual
-$2.34
Surprise
-16.00%
Exelixis Inc
Report Date
Aug 05, 2026 For Q2 26
Estimate
$0.80
Actual
$0.91
Surprise
+13.51%
Kymera Therapeutics, Inc. Common Stock
Report Date
Aug 05, 2026 For Q2 26
Estimate
-$0.73
Actual
-$0.62
Surprise
+15.25%
FAQ
What were AbCellera Biologics Inc. Common Shares's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, AbCellera Biologics Inc. Common Shares reported EPS of -$0.14, beating estimates by 29.86%, and revenue of $8.31M, 39.2% above expectations.
How did the market react to AbCellera Biologics Inc. Common Shares's Q1 2026 earnings?
The stock price moved up 0.19%, changed from $5.24 before the earnings release to $5.25 the day after.
When is AbCellera Biologics Inc. Common Shares expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for AbCellera Biologics Inc. Common Shares's next earnings report?
Based on 7
analysts, AbCellera Biologics Inc. Common Shares is expected to report EPS of -$0.14 and revenue of $7.94M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement